References
- Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. (2004). Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837–842.
- Bench T, Burkhoff D, O’Connell JB, Costanzo MR, Abraham WT, St John Sutton M, Maurer MS. (2009). Heart failure with normal ejection fraction: Consideration of mechanisms other than diastolic dysfunction. Curr Heart Fail Rep 6:57–64.
- Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. (2005). Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26:137–144.
- Corson MA, Jones PH, Davidson MH. (2008). Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 101:41F–50F.
- De Keulenaer GW, Brutsaert DL. (2008). Molecular mechanisms of diastolic dysfunction. In: Smiseth OA, Tendera M, ed. Diastolic Heart Failure. Ed. Springer, 3–20.
- Gerber Y, Dunlay SM, Jaffe AS, McConnell JP, Weston SA, Killian JM, Roger VL. (2009). Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community. Atherosclerosis 203:593–598.
- Hogg K, Swedberg K, McMurray J. (2004). Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:317–327.
- Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K. (2000). Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 296:151–161.
- Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, Dudley SC Jr. (2007). Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53:1652–1657.
- Pieske B. (2011). Heart failure with preserved ejection fraction-a growing epidemic or ‘The Emperor’s New Clothes?’. Eur J Heart Fail 13:11–13.
- Schmitz G, Ruebsaamen K. (2010). Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 208:10–18.
- Tschöpe C, Westermann D. (2009). Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. Herz 34:89–96.
- van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, Stricker BH, Witteman JC. (2006). Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study. Eur Heart J 27:2346–2352.